MiR-323b-5p acts as a novel diagnostic biomarker for critical limb ischemia in type 2 diabetic patients.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Diabetes Mellitus, Type 2/*complications ; Extremities/*blood supply ; Extremities/*pathology ; Ischemia/*diagnosis ; Ischemia/*genetics ; MicroRNAs/*metabolism; Aged ; Biomarkers/blood ; Biomarkers/metabolism ; Cluster Analysis ; Diabetes Mellitus, Type 2/blood ; Female ; Humans ; Ischemia/blood ; Logistic Models ; Male ; MicroRNAs/blood ; MicroRNAs/genetics ; Middle Aged ; ROC Curve ; Reproducibility of Results ; Risk Factors ; Statistics, Nonparametric

Type 2 diabetes mellitus (T2DM) is a major contributor to peripheral artery disease (PAD), especially in cases that advance to critical limb ischemia (CLI). Accumulating evidence indicates that miRNAs play an important role in the development of PAD and T2DM. Due to the limited value of current diagnostic methods for CLI in T2DM patients, we compared the miRNA expression profiles of Chinese T2DM patients with or without CLI to find out whether distinctive miRNAs could serve as potential diagnostic biomarkers. We statistically identified 7 miRNAs (hsa-miR-200b-3p, hsa-miR-2115-3p, hsa-miR-431-5p, hsa-miR-486-5p, hsa-miR-210-3p, hsa-miR-1264, hsa-miR-323b-5p) which were up-regulated in the CLI group, whereas other 4 miRNAs (hsa-miR-5579-3p, hsa-miR-665, hsa-miR-4285, hsa-miR-500a-3p) were down-regulated. Our validation test suggested a relatively high diagnostic accuracy of serum hsa-miR-323b-5p levels for the detection of CLI in T2DM patients, with a sensitivity of 62.67% and a specificity of 80.65%. The area under the curve (AUC) for miR-323b-5p + confounding risk factors was 0.94 (95% CI: 0.884-0.994, P < 0.001), which was higher than that for miR-323b-5p. Taken together, our results indicate that circulating hsa-miR-323b-5p could be a promising serum biomarker for the diagnosis of critical limb ischemia in type 2 diabetic patients.

High Throughput. 2017 Oct 06;6(4):null. (PMID: 29485611)
Sci Rep. 2017 Sep 12;7(1):11272. (PMID: 28900239)
Physiol Meas. 2004 Apr;25(2):R21-33. (PMID: 15132306)
Angiology. 2016 Nov;67(10):945-950. (PMID: 26980776)
Ann Intern Med. 2004 Sep 21;141(6):421-31. (PMID: 15381515)
Gene. 2017 Sep 20;629:101-107. (PMID: 28760552)
Eur Heart J. 2011 Nov;32(22):2851-906. (PMID: 21873417)
Int J Environ Res Public Health. 2016 Nov 08;13(11):. (PMID: 27834825)
Diabetes Care. 2014;37(5):1375-83. (PMID: 24478399)
JAMA. 2001 Sep 19;286(11):1317-24. (PMID: 11560536)
Circ Cardiovasc Genet. 2013 Oct;6(5):490-7. (PMID: 24129592)
Am J Cardiovasc Dis. 2018 Feb 05;8(1):1-13. (PMID: 29531852)
N Engl J Med. 1992 Feb 6;326(6):381-6. (PMID: 1729621)
Biochim Biophys Acta. 2016 Dec;1861(12 Pt B):2094-2103. (PMID: 26825686)
Diabetes. 2012 Nov;61(11):2937-47. (PMID: 22688339)
Eur J Vasc Endovasc Surg. 2011 Jan;41(1):110-6. (PMID: 21095144)
J Lipid Res. 2013 Dec;54(12):3491-505. (PMID: 24103848)
Front Endocrinol (Lausanne). 2018 Mar 28;9:132. (PMID: 29643835)
Diabetes. 2005 Jun;54(6):1615-25. (PMID: 15919781)
Nature. 2004 Sep 16;431(7006):350-5. (PMID: 15372042)
BMJ. 2018 Feb 1;360:j5842. (PMID: 29419394)
Lancet. 2016 Oct 8;388(10053):1545-1602. (PMID: 27733282)
Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):2143-50. (PMID: 25035341)
J Vasc Surg. 2011 Mar;53(3):676-83. (PMID: 21211928)
Diabetes Care. 2012 Oct;35(10):2000-4. (PMID: 22723344)
J Cardiovasc Risk. 1994 Dec;1(4):333-9. (PMID: 7621317)
BMJ. 2012 Aug 08;345:e4947. (PMID: 22875949)
Eur Heart J. 2015 Apr 14;36(15):932-8. (PMID: 25650396)
Diabetologia. 2015 May;58(5):900-11. (PMID: 25677225)
Circ Res. 2017 Feb 17;120(4):633-644. (PMID: 27895035)
Am Fam Physician. 1999 Apr 1;59(7):1899-908. (PMID: 10208708)
Cleve Clin J Med. 2006 Oct;73 Suppl 4:S2-7. (PMID: 17385385)
J Maine Med Assoc. 1960 Feb;51:58-60. (PMID: 14406262)
Vascul Pharmacol. 2011 Oct;55(4):79-86. (PMID: 21777698)
Arch Intern Med. 2000 Oct 23;160(19):2934-8. (PMID: 11041900)
PLoS Genet. 2012;8(5):e1002704. (PMID: 22589741)
Acta Pharmacol Sin. 2018 Jul;39(7):1100-1109. (PMID: 29565037)
Bioinformatics. 2016 May 1;32(9):1316-22. (PMID: 26743510)
J Diabetes. 2017 Apr;9(4):320-324. (PMID: 28070960)
Semin Vasc Surg. 1999 Jun;12(2):142-7. (PMID: 10777241)
Oncotarget. 2017 Oct 6;8(54):92801-92814. (PMID: 29190957)
Elife. 2015 Aug 12;4:null. (PMID: 26267216)
J Am Coll Cardiol. 2011 Nov 1;58(19):2020-45. (PMID: 21963765)
Nat Rev Drug Discov. 2013 Nov;12(11):847-65. (PMID: 24172333)
Front Endocrinol (Lausanne). 2018 Mar 20;9:74. (PMID: 29615970)
BMB Rep. 2012 Aug;45(8):464-9. (PMID: 22917031)
Int J Cancer. 2014 Sep 1;135(5):1187-94. (PMID: 24488924)
Methodist Debakey Cardiovasc J. 2012 Oct-Dec;8(4):10-4. (PMID: 23342182)
Int J Mol Sci. 2013 Nov 21;14(11):23086-102. (PMID: 24284400)
Diabetes Metab J. 2015 Aug;39(4):283-90. (PMID: 26301189)
Diabet Med. 2010 Jan;27(1):4-14. (PMID: 20121883)
In Vitro Cell Dev Biol Anim. 2018 Feb;54(2):99-110. (PMID: 29322359)
J Am Heart Assoc. 2017 May 3;6(5):null. (PMID: 28468784)
Cardiovasc Res. 2016 May 1;110(1):6-22. (PMID: 26912672)
Cell Biochem Biophys. 2014 Jan;68(1):25-35. (PMID: 23797610)
Arch Intern Med. 1999 Nov 8;159(20):2470-5. (PMID: 10665896)
J Transl Med. 2013 Jan 09;11:10. (PMID: 23302469)
Acta Diabetol. 2015 Oct;52(5):951-8. (PMID: 25990668)
Dtsch Arztebl Int. 2012 Feb;109(6):95-101. (PMID: 22396707)
J Dent Res. 2014 Jul;93(7 Suppl):86S-93S. (PMID: 24718111)
Angiology. 2010 May;61(4):392-6. (PMID: 19759029)

0 (Biomarkers)
0 (MIRN323 microRNA, human)
0 (MicroRNAs)

Date Created: 20181012 Date Completed: 20191023 Latest Revision: 20191023

20221213

PMC6179988

10.1038/s41598-018-33310-4

30305681